Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/32010| Title: | Ticagrelor or prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention for chronic coronary syndromes. | Austin Authors: | Koshy, Anoop N ;Giustino, Gennaro;Sartori, Samantha;Hooda, Amit;Feng, Yihan;Snyder, Clayton;Dasgupta, Shabitri;Kumar, Kartik R;Krishnamoorthy-Melarcode, Parasuram;Sweeny, Joseph;Khera, Sahil;Serrao, Gregory W;Sharma, Raman;Dangas, George;Kini, Annapoorna S;Mehran, Roxana;Sharma, Samin K | Affiliation: | The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Cardiology |
Issue Date: | 19-Jan-2023 | Date: | 2023 | Publication information: | EuroIntervention 2023; 18(15) | Abstract: | Potent P2Y12 inhibitors such as ticagrelor and prasugrel are superior to clopidogrel in acute coronary syndrome (ACS) patients treated with percutaneous coronary intervention (PCI). Whether this benefit extends to a patient population with chronic coronary syndromes (CCS) is unclear. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/32010 | DOI: | 10.4244/EIJ-D-22-00654 | ORCID: | Journal: | EuroIntervention : Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology | PubMed URL: | 36660810 | ISSN: | 1969-6213 | Type: | Journal Article |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.